Key result
In vitro, simvastatin significantly inhibited CES1-catalyzed hydrolysis of clopidogrel and its metabolites but did not alter the net formation of the clopidogrel active metabolite.
Why the study?
Does simvastatin alter the formation of the clopidogrel active metabolite in human liver s9 fractions?
Population
In vitro human liver s9 fraction
Comparison
Simvastatin vs Clopidogrel alone (implied)
Design
Preclinical
Authors
Loading...
Simvastatin does not reduce clopidogrel active metabolite in vitro; leaves open any clinical interaction or CES1 relevance in patients.
Does simvastatin alter the formation of the clopidogrel active metabolite in human liver s9 fractions?
In vitro evidence shows that simvastatin does not alter the production of clopidogrel's active metabolite, supporting clinical observations that their concomitant use does not significantly influence clinical outcomes.
Wang et al. (2015) studied Drug-drug interaction between clopidogrel and simvastatin. Simvastatin vs. Control (absence of simvastatin) was evaluated on Formation of clopidogrel active metabolite (clopidogrel-AM). In vitro, simvastatin significantly inhibited CES1-catalyzed hydrolysis of clopidogrel and its metabolites but did not alter the net formation of the clopidogrel active metabolite.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: